TLRY Tilray Brands, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1731348 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.9%
TTM net income YoY92.4%
TTM EPS YoY94.2%
Revenue 3-yr CAGR14.0%
Net income 3-yr CAGR—
Margins
Gross margin29.1%
Operating margin-9.3%
Net margin-17.1%
FCF margin—
EBITDA margin—
Returns
ROE-10.4%
ROA-7.4%
ROIC (approx.)-5.0%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.08x
Current ratio1.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.51x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-08-31 | 2026Q4*2026-05-31 | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $257.15M | $281.71M | $206.73M | $217.51M | $209.50M | $224.53M | $185.78M | $210.95M |
| Cost of revenue | $179.64M | $191.19M | $151.78M | $160.01M | $152.03M | $156.90M | $133.77M | $149.73M |
| Gross profit | $77.51M | $90.52M | $54.95M | $57.50M | $57.47M | $67.63M | $52.01M | $61.22M |
| R&D expense | $89,000 | $180,000 | $62,000 | $78,000 | $41,000 | $34,000 | $85,000 | $60,000 |
| SG&A expense | $57.61M | $61.17M | $50.23M | $51.17M | $41.05M | $37.97M | $39.25M | $46.00M |
| Operating income | -$24.05M | -$16.45M | -$26.39M | -$22.28M | $2.09M | -$1.44B | -$759.93M | -$42.22M |
| Pretax income | -$38.31M | -$24.07M | -$23.26M | -$39.96M | -$772,000 | -$1.39B | -$792.33M | -$83.24M |
| Income tax | $1.73M | $13.86M | $1.97M | $3.55M | -$2.29M | -$125.14M | $1.20M | $2.04M |
| Net income | -$43.14M | -$49.57M | -$26.57M | -$44.93M | -$322,000 | -$1.27B | -$789.44M | -$85.34M |
| EPS (basic) | -0.32 | — | -0.24 | -0.41 | 0.00 | — | -8.69 | -0.99 |
| EPS (diluted) | -0.32 | — | -0.24 | -0.41 | 0.00 | — | -8.69 | -0.99 |
| Weighted avg. shares (diluted) | 133.34M | — | 112.68M | 110.34M | 106.03M | — | 90.83M | 86.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $214.96M | $225.98M | $204.62M | $246.70M | $264.83M | $221.67M | — | $189.70M |
| Short-term investments | $3.05M | $5.29M | $15.31M | $44.85M | $0 | $34.70M | — | $62.55M |
| Receivables | $190.62M | $189.17M | $118.37M | $109.07M | $107.08M | $121.49M | — | $112.74M |
| Inventory | $328.97M | $301.19M | $292.30M | $283.20M | $282.79M | $270.88M | $263.40M | $266.01M |
| Current assets | $807.59M | $792.13M | $718.76M | $729.32M | $701.14M | $688.63M | — | $707.34M |
| PP&E, net | $665.92M | $680.23M | $543.01M | $550.10M | $680.23M | $568.43M | $537.80M | $554.42M |
| Goodwill | $752.35M | $752.35M | $752.35M | $752.35M | $752.35M | $752.35M | $1.30B | $2.00B |
| Intangibles | $42.47M | $42.78M | $23.34M | $21.73M | $25.17M | $21.42M | $847.22M | $866.64M |
| Total assets | $2.33B | $2.33B | $2.07B | $2.10B | $2.08B | $2.07B | — | $4.19B |
| Current liabilities | $430.69M | $358.38M | $257.54M | $259.31M | $267.63M | $280.30M | — | $278.52M |
| Short-term debt | $8.69M | $8.78M | $8.83M | $8.57M | $8.19M | $7.18M | — | $17.75M |
| Long-term debt | $118.05M | $120.42M | — | — | — | — | — | — |
| Total debt | $126.73M | $129.20M | — | — | — | — | — | — |
| Total liabilities | $721.28M | $733.14M | $549.12M | $552.09M | $561.99M | $584.75M | — | $738.15M |
| Shareholders' equity | $1.62B | $1.61B | $1.56B | $1.58B | $1.54B | $1.51B | $2.70B | $3.47B |
| Net debt | -$88.23M | -$96.78M | — | — | — | — | — | — |
| Shares outstanding | 144.94M | 131.68M | 116.55M | 116.52M | 1.12B | 106.07M | 983.37M | 929.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.54M | -$37.32M | -$21.94M | -$8.54M | -$1.34M | -$12.81M | -$5.76M | -$40.72M |
| Capital expenditure | — | — | — | — | — | $6.33M | $14.41M | $5.44M |
| Free cash flow | — | — | — | — | — | -$19.14M | -$20.18M | -$46.16M |
| Investing cash flow | -$9.25M | -$51.18M | $28.92M | -$58.01M | $24.47M | $13.52M | -$119,000 | -$10.72M |
| Financing cash flow | $13.97M | $68.17M | -$5.13M | $48.10M | $19.85M | $16.64M | $18.07M | $38.20M |
| Stock-based compensation | $6.58M | $14.88M | $13.72M | $12.28M | $5.05M | $6.10M | $4.04M | $7.24M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.